| Literature DB >> 25158232 |
Naoko Yui1, Hirotaka Yoshioka2, Hiroto Fujiya3, Haruki Musha4, Moroe Beppu5, Rie Karasawa6, Kazuo Yudoh7.
Abstract
Apurinic/apyrimidinic endonuclease 2 (Apex 2) plays a critical role in DNA repair caused by oxidative damage in a variety of human somatic cells. We speculated that chondrocyte Apex 2 may protect against the catabolic process of articular cartilage in osteoarthritis (OA). Higher levels of Apex 2 expression were histologically observed in severely compared with mildly degenerated OA cartilage from STR/OrtCrlj mice, an experimental model which spontaneously develops OA. The immunopositivity of Apex 2 was significantly correlated with the degree of cartilage degeneration. Moreover, the OA-related catabolic factor interleukin-1β induced the expression of Apex 2 in chondrocytes, while Apex 2 silencing using small interfering RNA reduced chondrocyte activity in vitro. The expression of Apex 2 in chondrocytes therefore appears to be associated with the degeneration of articular cartilage and could be induced by an OA-related catabolic factor to protect against the catabolic process of articular cartilage. Our findings suggest that Apex 2 may have the potential to prevent the catabolic stress-mediated down-regulation of chondrocyte activity in OA.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25158232 PMCID: PMC4200784 DOI: 10.3390/ijms150914921
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Expression of Safranin O (SO) staining and Apex 2 (apurinic/apyrimidinic endonuclease 2) immunohistological staining in articular cartilage of STR/OrtCrlj mice. (A,B) Representative images of Safranin O staining and Apex 2 immunohistological staining in mild osteoarthritis (OA) articular cartilages from STR/OrtCrlj mice; Safranin O staining (×25) (a);Safranin O staining (×200) (b); Control antibody (c);Apex2 immunostaining (d). Almost of the mildly degenerated cartilages were negative for Apex 2 immunostaining; (C,D) Representative images of Safranin O staining and Apex 2 immunohistological staining in severe OA articular cartilages from STR/OrtCrlj mice; Safranin O staining (×25) (a); Safranin O staining (×200) (b); Control antibody (c); Apex 2 immunostaining (d). A higher expression pattern of Apex 2 was observed in the severely degenerated cartilages. Immunopositivity for Apex 2 was predominant in the severe OA cartilages compared with the mild degenerated cartilages.
Figure 2Correlation between Apex 2 expression and degree of cartilage degeneration in OA mouse model.
Figure 3Expressions of Apex 2 in chondrocytes. (A) Expression of Apex 2 in normal chondrocytes from patients with traumatic femoral neck fractures in the presence of IL-1β (10 ng/mL); (B) Expression of Apex 2 in OA chondrocytes from patients with OA in the presence of IL-1β (10 ng/mL); and (C) Time course of Apex 2 expression in OA chondrocytes in the presence of IL-1β (10 ng/mL). The level of Apex 2 expression was analyzed as a relative ratio against the level of expression of Apex 2 at initial phase (0 hour-incubation).
Figure 4siRNA-mediated downregulation of Apex 2 mRNA reduces chondrocyte activity. To address whether Apex 2 is necessary to prevent catabolic factor-induced changes in chondrocyte activitys, the Apex 2 mRNA levels were silenced using siRNAs. (A) The siRNA against Apex 2 reduced the expression of Apex 2 protein expression by ~40% compared with scrambled control siRNA treatment; (B) In normal chondrocytes, silencing of Apex 2 with siRNAs did not influence the chondrocyte activity evaluated by aggrecan production;(C) In OA chondrocytes, silencing of Apex 2 with siRNAs significantly inhibited the chondrocyte activity evaluated by aggrecan production (* p < 0.05).
Modified Mankin Score (criteria for histological evaluation).
| Category | Score | Criteria for Histologic Evaluation |
|---|---|---|
| Safranin O-Fast Green Staining | 0 | uniform staining throughout articular cartilage |
| 1 | loss of staining in the superficial zone for less than one-half of the length of the plateau | |
| 2 | loss of staining in the superficial zone for one-half or more of the length of the plateau | |
| 3 | loss of staining in the superficial and middle zones for less than one-half of the length of the plateau | |
| 4 | loss of staining in the superficial and middle zones for one-half or more of the length of the plateau | |
| 5 | loss of staining in all 3 zones for less than one-half of the length of the plateau | |
| 6 | of staining in all 3 zones for one-half or more of the length of the plateau | |
| Chondrocyte Loss | 0 | no decrease in cells |
| 1 | minimal decrease in cells | |
| 2 | moderate decrease in cells | |
| 3 | marked decrease in cells | |
| 4 | very extensive decrease in cells | |
| Structure | 0 | normal |
| 1 | surface irregularities | |
| 2 | 1–3 superficial clefts | |
| 3 | 3 superficial clefts | |
| 4 | 1–3 clefts extending into the middle zone | |
| 5 | >3 clefts extending into the middle zone | |
| 6 | 1–3 clefts extending into the deep zone | |
| 7 | >3 clefts extending into the deep zone | |
| 8 | clefts extending to calcified cartilage |